Evofem Biosciences to Present at LD Micro Investor Conference on October 12, 2021
Evofem Biosciences (NASDAQ: EVFM) announced its CEO, Saundra Pelletier, will present at the LD Micro Main Event in Los Angeles from October 12-14, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evofem Biosciences (NASDAQ: EVFM) announced its CEO, Saundra Pelletier, will present at the LD Micro Main Event in Los Angeles from October 12-14, 2021. The presentation is scheduled for October 12 at 12:30 p.m. PT. The company recently launched a new campaign, "House Rules," on September 9, 2021, to promote its hormone-free contraceptive, Phexxi. The campaign has successfully increased media coverage, site traffic, and telehealth visits, enhancing Phexxi prescription growth. Interested parties can register for the virtual presentation via the company website.
Details
News Market Reaction – EVFM
The recorded move for EVFM in the trading session of this news was +3.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at the 14th annual LD Micro Main Event being held in Los Angeles on October 12-14, 2021.
Date: | Tuesday, October 12, 2021 |
Time: | 12:30 p.m. PT (3:30 p.m. ET) |
Location: | Luxe Sunset Bel Air (Los Angeles), Track 1 |
Evofem recently launched its new direct-to-consumer campaign "House Rules" focused on building awareness of its hormone-free contraceptive, Phexxi® (lactic acid, citric acid and potassium bitartrate), while empowering women to kiss hormonal contraception goodbye.
The campaign, which launched September 9, 2021, has garnered significant media coverage and is driving increased site sessions and telehealth visits on Phexxi.com and Phexxi prescription growth.
Register to watch the virtual presentation at https://me21.mysequire.com/ or through the Investors section of the company's website, under "Events & Presentations."
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi, is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-ld-micro-investor-conference-on-october-12-2021-301388698.html
SOURCE Evofem Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.